Belsomra (Suvorexant) Safety Signals and FDA Actions

Does Belsomra Have a Boxed Warning?

No. The current Belsomra prescribing information has no boxed warning [1].

This point is easy to confuse with the FDA's April 2019 action involving three other insomnia medicines: eszopiclone (Lunesta), zaleplon (Sonata), and zolpidem (Ambien and related products). The FDA required a boxed warning for those three drugs after reviewing serious injuries and deaths associated with complex sleep behaviors [2]. Suvorexant was not one of the medicines named in that boxed-warning action.

Belsomra does have a warning about complex sleep behaviors in section 5.3 of its label. Reported behaviors include sleepwalking, sleep-driving, and other activities performed while not fully awake. They can occur after the first or a later dose, with or without alcohol or another central nervous system depressant. The label instructs patients to discontinue Belsomra immediately if a complex sleep behavior occurs [1].

That distinction matters. A non-boxed warning can still describe a serious risk, but calling it a boxed warning misstates the FDA's regulatory action.

What the Current FDA Label Actually Says

The current label identifies six main warning areas [1]:

1. CNS depression and daytime impairment. Suvorexant can impair alertness and motor coordination. Risk rises with dose, and people taking 20 mg are cautioned about next-day driving and other activities requiring full alertness.
2. Worsening depression or suicidal thinking. The label describes a dose-related increase in suicidal ideation in clinical studies and advises prompt evaluation of new behavioral changes.
3. Complex sleep behaviors. Sleepwalking, sleep-driving, preparing food, making calls, having sex, and other activities while not fully awake have been reported. The drug should be stopped immediately if this occurs.
4. Sleep paralysis, hallucinations, and cataplexy-like symptoms. These effects are consistent with blocking the orexin wake-promoting system and may increase with dose.
5. Compromised respiratory function. Clinicians should consider respiratory effects in people with impaired breathing. The drug has not been studied in severe obstructive sleep apnea or severe chronic obstructive pulmonary disease.
6. Persistent insomnia. Failure to improve within 7 to 10 days can indicate an unrecognized medical or psychiatric condition that needs evaluation.

The label's only listed contraindication is narcolepsy [1]. Strong CYP3A inhibitors and severe hepatic impairment are described as “not recommended,” not “contraindicated.”

Next-Day Somnolence and Driving

Somnolence was the most common adverse reaction in the controlled insomnia trials. In pooled three-month data at labeled doses, somnolence occurred more often with suvorexant than placebo, and the risk increased with dose [1][3].

Driving studies are more nuanced than a simple “safe” or “unsafe” label. In a controlled on-the-road study, mean driving performance after suvorexant did not cross the prespecified threshold for clinically meaningful impairment, but some participants stopped tests early because they felt too sleepy and individual responses varied [4]. The prescribing information therefore tells patients not to drive or perform other hazardous activities unless they feel fully awake, and specifically cautions people taking 20 mg against next-day driving [1].

Taking the medicine later than directed, leaving fewer than 7 hours before planned awakening, combining it with alcohol or another sedative, or using a higher dose can increase impairment.

Complex Sleep Behaviors

Complex sleep behavior is a label-recognized risk, but spontaneous reports cannot establish how often it occurs. Reports are voluntary, the number of exposed people is uncertain, and other drugs, alcohol, sleep disorders, or medical conditions may contribute.

The practical response is clear:

• Stop Belsomra immediately after any episode of activity while not fully awake.
• Do not take another dose until the prescribing clinician has evaluated the event.
• Seek urgent help for injury, suspected overdose, severe confusion, or danger to the patient or others.
• Avoid alcohol and discuss all other sedating medicines with the prescriber.

Sleep Paralysis, Hallucinations, and Cataplexy-Like Symptoms

Orexin signaling helps maintain wakefulness. Suvorexant blocks both OX1R and OX2R receptors, so sleep paralysis, hallucinations around sleep onset or awakening, and transient leg weakness can occur as on-target effects [1][5].

These symptoms do not automatically mean a person has narcolepsy, but recurrent episodes warrant clinical review. Belsomra is contraindicated in patients who already have narcolepsy [1].

Depression and Suicidal Thinking

The label warns that depression can worsen and suicidal thinking can occur. People with depression may be at higher risk, but insomnia itself is also associated with psychiatric illness, so an individual report does not prove the drug caused the event [1].

Patients and families should contact the prescriber promptly for new or worsening depression, suicidal thoughts, unusual agitation, or major behavioral change. Imminent self-harm risk requires emergency help.

Falls and Use in Older Adults

Suvorexant can cause drowsiness and impaired coordination, which can contribute to falls. The label states that older people have a higher risk of falls and advises caution, while also stating that no age-based dose adjustment is required solely because a patient is older [1].

The 2023 AGS Beers Criteria specifically identify nonbenzodiazepine benzodiazepine-receptor agonist hypnotics such as zolpidem, eszopiclone, and zaleplon as potentially inappropriate in many older adults [6]. They do not support the prior claim that every hypnotic, including suvorexant, is automatically listed in the same category. Medication choice still requires an individualized review of fall history, cognition, other sedatives, and sleep-disorder diagnoses.

Respiratory Safety

A randomized crossover study in people with mild to moderate obstructive sleep apnea tested suvorexant 40 mg, twice the current maximum labeled dose. The average apnea-hypopnea effect was small, but variability prevented the investigators from excluding clinically important respiratory effects in every patient [7].

That study does not establish safety in severe obstructive sleep apnea, severe chronic obstructive pulmonary disease, or in combination with opioids or other respiratory depressants. The current label advises considering respiratory function before prescribing [1].

CYP3A Drug Interactions

Metabolism by CYP3A is the principal elimination pathway for suvorexant [1][8].

Strong CYP3A inhibitors: Concomitant use with drugs such as ketoconazole, itraconazole, posaconazole, clarithromycin, and ritonavir is not recommended. Ketoconazole increased suvorexant exposure to roughly 2.7 times the exposure without the inhibitor [1]. This is an avoidance recommendation, not an FDA contraindication.

Moderate CYP3A inhibitors: With drugs such as diltiazem, erythromycin, fluconazole, or verapamil, the recommended Belsomra dose is 5 mg and generally should not exceed 10 mg [1].

Strong CYP3A inducers: Rifampin, carbamazepine, and phenytoin can substantially lower suvorexant exposure and reduce efficacy [1].

Alcohol and other CNS depressants: Alcohol produced additive psychomotor impairment. Other sedatives can also increase impairment, and dose reduction of one or both medicines may be necessary [1].

Hepatic, Renal, Pregnancy, and Lactation Considerations

• Renal impairment: The label does not require a renal dose adjustment [1].
• Hepatic impairment: No adjustment is required for mild or moderate hepatic impairment; use in severe hepatic impairment is not recommended [1].
• Pregnancy: Human data are insufficient to establish a drug-associated risk. The current label uses a narrative risk summary, not the discontinued letter-category system [1].
• Lactation: Suvorexant is present in human milk in low concentrations. The clinician should weigh breastfeeding benefits, the mother's need for treatment, and possible effects on the infant [1].

Postmarketing Reports: What They Can and Cannot Show

The label lists postmarketing reports of palpitations, tachycardia, nausea, vomiting, psychomotor hyperactivity, anxiety, and pruritus [1]. Because these reports come from an uncertain exposed population and are submitted voluntarily, they cannot reliably estimate incidence or prove causation.

The FDA Adverse Event Reporting System is useful for detecting signals that merit study. It should not be used to rank drugs by raw report counts or to calculate patient-level risk without appropriate denominators and comparison methods.

When to Contact a Clinician

Contact the prescribing clinician promptly for:

• next-day impairment that affects driving or work;
• sleep paralysis, hallucinations, or transient weakness;
• worsening depression, suicidal thoughts, or marked behavioral change;
• repeated falls, severe dizziness, or confusion;
• new breathing problems during sleep; or
• lack of meaningful insomnia improvement after 7 to 10 days.

Stop Belsomra immediately and contact the prescriber after any complex sleep behavior. Seek emergency care for serious injury, overdose, inability to awaken normally, breathing difficulty, or imminent self-harm risk.